Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to 49.0%
Operating margin was 49.0% in Q1 FY2026, up 4.2 pp from a year earlier. On a trailing-twelve-month basis it was 44.8%, up 1.6 pp year over year. Over 3 fiscal years it narrowed by 3.8 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 2 analysts of 40.4% for the fiscal year ending Dec 2026, down from 43.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 49.0%+8.5 pp QoQ
- Last fiscal yearDec 2025
- 43.8%+4.1 pp YoY
- LTMMar 2026
- 44.8%+1.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.2 pp | -4.8 pp | -9.0 pp |
| 1 year | +4.1 pp | -3.3 pp | -7.4 pp |
| 3 years | -3.8 pp | -3.3 pp | +0.4 pp |
| 5 years | -3.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 43.8%
- Year-over-year change
- +4.1pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.8% | +4.1pp |
| FY2024 | 2024-12-31 | 39.7% | +17.9pp |
| FY2023 | 2023-12-31 | 21.8% | -25.7pp |
| FY2022 | 2022-12-31 | 47.5% | +10.3pp |
| FY2021 | 2021-12-31 | 37.2% | — |
Operating Margin vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 operating margin of 44.8% is the highest of the 8 companies compared; the peer median is -242.3%.
- Its year-over-year change of +1.6 pp is the lowest of 7, against a peer median of +257.9 pp.
- Over three fiscal years its change of -3.8 pp compares with a peer median of +68.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 44.8% | +1.6 pp | -3.8 pp | |
| LTM Jun 2026 | 11.9% | +11.1 pp | +7.0 pp | |
| LTM Jun 2026 | -12.2% | +46.9 pp | +87.4 pp | |
| LTM Mar 2026 | -81.4% | +5066.4 pp | +49.9 pp | |
| LTM Jun 2026 | -242.3% | +497.7 pp | +281.0 pp | |
| LTM Mar 2026 | -720.0% | +468.9 pp | +1858.2 pp | |
| LTM Jun 2026 | -991.7% | +16.5 pp | -248.6 pp | |
| LTM Sep 2026 | -71732.3% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CPRX) | -242.3% | +257.9 pp | +68.6 pp | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 140.83M | 214.2M | 398.2M | 491.73M | 588.99M |
| Cost of Revenue | 21.88M | 34.39M | 51.97M | 68.85M | 87.25M |
| Gross Profit | 118.95M | 179.81M | 346.24M | 422.89M | 501.74M |
| Gross Margin | 84.5% | 83.9% | 86.9% | 86.0% | 85.2% |
| Research & Development | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
| Selling, General & Admin | 49.63M | 57.09M | 133.71M | 177.74M | 193.75M |
| Operating Expenses | 66.56M | 77.97M | 259.43M | 227.77M | 243.96M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| EBITDA | 52.86M | 105.96M | 127.39M | 254.04M | 321.39M |
| EBITDA Margin | 37.5% | 49.5% | 32.0% | 51.7% | 54.6% |
| Operating Income | 52.39M | 101.84M | 86.81M | 195.12M | 257.78M |
| Operating Margin | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Interest Income | 0 | 0 | 0 | 16.06M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 282K | 2.88M | 7.7M | 21.14M | 25.74M |
| Income Before Tax | 52.67M | 104.72M | 94.51M | 216.26M | 283.52M |
| Pre-Tax Margin | 37.4% | 48.9% | 23.7% | 44.0% | 48.1% |
| Income Tax Expense | 13.19M | 21.64M | 23.1M | 52.37M | 69.19M |
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Net Margin | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| EPS (Basic) | 0.38 | 0.80 | 0.67 | 1.38 | 1.75 |
| EPS (Diluted) | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| Weighted Avg Shares | 103.38M | 103.37M | 106.28M | 118.46M | 122.29M |
| Weighted Avg Shares (Diluted) | 107.8M | 111.38M | 113.75M | 124.94M | 127.26M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.